GlaxoSmithKline Cash Flow from Operations

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline PLC cash flow from operations fundamental analysis lookup allows you to check this and other indicators for GlaxoSmithKline PLC or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Cash Flow from Operations

 
Refresh
GlaxoSmithKline PLC Net Cash Flow from Operations is increasing as compared to previous years. The last year's value of Net Cash Flow from Operations was reported at 9.53 Billion. The current Free Cash Flow per Share is estimated to increase to 3.12, while Cash Flow Per Share is estimated to decrease to 1.37.

GlaxoSmithKline Cash Flow from Operations Analysis

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

  GlaxoSmithKline PLC Market Capitalization

Operating Cash Flow 
 = 
EBITDA 
-  
Taxes 
More About Cash Flow from Operations | All Equity Analysis

Current GlaxoSmithKline PLC Cash Flow from Operations

(5.78 B)

GlaxoSmithKline Cash Flow from Operations Over Time Pattern

 GlaxoSmithKline PLC Net Cash Flow from Operations 
      Timeline 

About Cash Flow from Operations

Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Compare to competition

GlaxoSmithKline PLC Cash Flow from Operations Related Assessment

  Net Cash Flow from Operations

In accordance with the recently published financial statements GlaxoSmithKline PLC has -5.78E9 in Cash Flow from Operations. This is 1196.22% lower than that of the Healthcare sector, and significantly lower than that of Drug Manufacturers?General industry, The Cash Flow from Operations for all stocks is 695.13% higher than the company.

GlaxoSmithKline Cash Flow from Operations Peer Comparison

  Cash Flow from Operations 
      GlaxoSmithKline PLC Comparables 
GlaxoSmithKline PLC is rated below average in cash flow from operations category among related companies.

GlaxoSmithKline PLCCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee234.94 K236.26 K280.09 K306.57 K322.77 K339.45 K297.49 K
Average Assets41.37 B47.05 B56.26 B57.73 B57.22 B68.88 B64.51 B
Earnings before Tax2.89 B10.58 B1.79 B2.89 B4.38 B5.6 B5.21 B
Average Equity5.63 B4.69 B3.12 B528 M1.86 B7.59 B6.44 B
Enterprise Value135.45 B130.34 B118.87 B112.37 B121.13 B155.97 B157.75 B
Free Cash Flow5.13 B3.32 B6.66 B6.99 B8.57 B8.36 B8.31 B
Invested Capital29.76 B29 B29.23 B19.77 B34.77 B39.93 B37.66 B
Tangible Asset Value28.61 B31.61 B34.34 B33.09 B35.08 B38.17 B38.38 B
Working Capital1.38 B3.17 B(2.29 B)(10.66 B)(5.56 B)(4.56 B)(4.68 B)
Interest Coverage5.2816.123.495.68136.42146.89158.48
Calculated Tax Rate4.6620.4945.3538.6115.8115.523.02
PPandE Turnover2.572.562.722.792.813.153.33
Receivables Turnover4.734.995.085.325.255.214.85
Inventory Turnover2.181.81.981.891.941.862.08
Operating Margin14.2941.777.8912.3616.8219.5822.25
Return on Investment13.6144.6210.5620.221.8518.2823.2
Cash Flow Per Share1.060.531.321.41.71.611.37
Revenue to Assets0.570.450.470.540.530.420.55
Quick Ratio0.660.830.560.360.450.480.63
Asset Turnover0.630.560.510.50.520.540.49
Book Value per Share1.61.910.42(0.025)1.414.244.57
Current Ratio1.11.240.880.60.750.810.86
Debt to Equity Ratio8.388.7248.15(777.82)14.395.385.8
Dividend Yield0.0620.0610.0720.0580.0560.0430.0541
EBITDA Margin0.160.470.0910.120.170.190.2

GlaxoSmithKline Fundamentals

About GlaxoSmithKline PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Receivables5.67 B6.08 B6.87 B5.97 B
Inventories5.56 B5.48 B5.95 B5.09 B


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page